Researcher:
Somay, Kayra

Profile Picture
ORCID

OrgUnit Logo
Organizational Unit

Job Title

Researcher

First Name

Kayra

Last Name

Somay

Name

Name Variants

Somay, Kayra

Email Address

Birth Date

Filters

2020 - 20248

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.26c68220-4697-4057-9c3a-b4c19b17d04c

Search Results

Now showing 1 - 8 of 8
  • Placeholder
    PublicationMetadata only
    Hepatitis delta virus infection in Turkey: a meta analysis of prevalence
    (Elsevier, 2023) Toy, Mehlika; ŞentĆ¼rk, BegĆ¼m GĆ¼ler; Somay, Kayra; GenƧdal, Genco; Yurdaydın, Cihan; School of Medicine; KoƧ University Hospital
    N/A
  • Placeholder
    PublicationMetadata only
    Hepatitis delta virus infection in Turkey: a meta-analysis of prevalence
    (Elsevier, 2024) Toy, Mehlika; ŞentĆ¼rk, BegĆ¼m GĆ¼ler; Somay, Kayra; GenƧdal, Genco; Yurdaydın, Cihan; School of Medicine; KoƧ University Hospital
    Objectives: Hepatitis delta virus (HDV) infection has been granted orphan disease status by the US Food and Drug Administration and the European Medicines Agency owing to its rarity and relatively limited research and treatment options. Turkey is considered an endemic country for the virus. We aimed to provide a current and updated country- and region-specific HDV infection prevalence. Methods: In this meta-analysis, we searched databases, including MEDLINE, PUBMED, EMBASE, and UlakBim (Turkish Medical Index) published between January 1, 2006, and December 31, 2022. We included blood donor studies, outpatient clinic studies that comprised patients without cirrhosis, and inpatient clinical studies that comprised patients with cirrhosis. Turkey was divided into three regions: West, Central, and East Turkey. Results: After a systematic assessment, 41 studies were included. Using a random-effects model, the estimated HDV prevalence among hepatitis B surface antigen-positive blood donors, outpatient clinic, and inpatient clinic patients were 3.37% (confidence interval [CI] 1.99-6.11), 5.05% (CI 4.00-6.23), and 29.06% (CI 10.45-51.79), respectively. The HDV prevalence among outpatient clinic patients in Western, Central, and Eastern regions were 3.38% (CI 2.47-4.44), 2.15% (CI 1.37-3.09), and 9.81% (CI 6.61-13.55), respectively. Conclusions: East Turkey continues to have a high burden of HDV. Public health efforts, such as screening, should be targeted accordingly.
  • Placeholder
    PublicationMetadata only
    T-cell sub group analysis and T-cell exhaustion after autologous stem cell transplantation in lymphoma patients
    (Springernature, 2023) Somay, Kayra; Birtaş Ateşoğlu, Elif; Albayrak, ƖzgĆ¼r; Kızılırmak, Ali Burak; Akan, Tuba; Ferhanoğlu, Ahmet Burhan; KoƧ University Research Center for Translational Medicine (KUTTAM) / KoƧ Ɯniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); Graduate School of Health Sciences; School of Medicine; KoƧ University Hospital
    N/A
  • Placeholder
    PublicationMetadata only
    Immature platelet fraction: Is a novel early predictive marker for disease severity in patients with Covid-19 pneumonia?
    (De Gruyter Open Ltd, 2021) Tasdemir, Z.A.; Palaoğlu, K.E.; N/A; Ä°ncir, Said; Komesli, Zeynep; BaygĆ¼l, Arzu Eden; Ƈaltı, Hatice Kant; Kapmaz, Mahir; Tekin, SĆ¼da; KılıƧ, Alparslan; Dağel, Tuncay; Okan, Ayşe; Somay, Kayra; Akpınar, Timur SelƧuk; Doctor; Doctor; Faculty Member; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Faculty Member; N/A; N/A; School of Medicine; N/A; N/A; N/A; N/A; N/A; N/A; N/A; School of Medicine; KoƧ University Hospital; KoƧ University Hospital; N/A; KoƧ University Hospital; KoƧ University Hospital; KoƧ University Hospital; KoƧ University Hospital; KoƧ University Hospital; KoƧ University Hospital; KoƧ University Hospital; N/A; 175430; N/A; 272290; N/A; N/A; 42146; N/A; N/A; N/A; N/A; 216646
    Objectives : In many diseases, immature platelet fraction (IPF%) is related to coagulopathy and poor outcome. This study aimed to investigate the predictive value of IPF% for the severity of pneumonia in patients with Coronavirus Disease 2019 (COVID-19). Methods : A total of 154 patients with COVIDā€19 infections were included. The patients were divided into two groups according to the severity of pneumonia (severe and non-severe) regarding their oxygen demand. Results : Given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p<0.001). Mean platelet volume (p<0.001), platelet-large cell ratio (p=0.001), platelet distribution width (p=0.001), D-Dimer (p<0.001), INR (p=0.003), and aPTT (p=0.007) were also found to be significantly higher in the severe group. Moreover, IPF (p=0.014, Odds ratio = 2.000, 95%CI: 1.149-3.482) was an independent predictor for the severity. The curve value from receiver operating characteristics was 0.879 (p<0.001, 95%CI: 0.784-0.943) for determining the severity of pneumonia. IPF% had a sensitivity and specificity value of 69.5 and 92.4% to detect the diseaseā€™s severity. Conclusions : IPF% is an independent predictor for the severity of COVID-19 pneumonia. Assessment of IPF% may both help to early determine high-risk patients with COVID-19 and to alert the physicians. / AmaƧ : Pek Ƨok hastalıkta, immatĆ¼r platelet fraksiyonu (%Ä°PF), koagĆ¼lopati ve kƶtĆ¼ sonuƧla ilişkilidir. Bu Ƨalışma, Coronavirus Hastalığı 2019 (COVID-19) olan hastalarda pnƶmoni şiddeti iƧin %Ä°PFā€™nin prediktif değerini araştırmayı amaƧladı. Yƶntem : COVID-19 enfeksiyonu olan toplam 154 hasta dahil edildi. Hastalar, oksijen ihtiyaƧları gƶz ƶnĆ¼ne alınarak pnƶmoni şiddetine gƶre (ağır ve ağır olmayan) iki gruba ayrıldı. Bulgular : Laboratuvar parametrelerine bakıldığında, medyan Ä°PF yĆ¼zdesi ağır grupta anlamlı olarak daha yĆ¼ksekti (%11.9ā€²a karşı %3.9, p<0.001). Ortalama trombosit hacmi (p<0.001), trombosit-bĆ¼yĆ¼k hĆ¼cre oranı (p=0.001), trombosit dağılım genişliği (p=0.001), D-Dimer (p<0.001), Ä°NR (p=0.003) ve aPTT (p=0.007) ağır grupta anlamlı olarak daha yĆ¼ksek bulundu. Ayrıca, Ä°PF (p=0.014, Odds oranı = 2.000, %95 CI: 1.149-3.482) hastalık şiddeti iƧin bağımsız bir ƶngƶrdĆ¼rĆ¼cĆ¼ olarak bulundu. Algılayıcı işletim eğrisinden gelen eğri değeri, pnƶmoni şiddetini belirlemek iƧin 0.879 (p<0.001, %95 CI: 0.784-0.943) idi. Ä°PF, hastalığın şiddetini saptamak iƧin %69.5ā€²lik duyarlılık ve %92.4ā€²lĆ¼k ƶzgĆ¼llĆ¼k değerine sahipti. SonuƧ : Ä°PF, COVID-19 pnƶmonisinin şiddeti iƧin bağımsız bir ƶngƶrĆ¼cĆ¼dĆ¼r. %Ä°PFā€™nin değerlendirilmesi, hem COVID-19ā€²lu yĆ¼ksek riskli hastaları erken belirlemeye hem de hekimleri uyarmaya yardımcı olabilir.
  • Thumbnail Image
    PublicationOpen Access
    An unusual case of extrapulmonary tuberculosis in rheumatology consultation
    (Aves, 2022) Somay, Kayra; Eren, Ä°lker; Kapmaz, Mahir; Ƈağlayan, Benan Niku; Karakaya, Afak Durur; Kanıtez, NilĆ¼fer Alpay; Researcher; Faculty Member; Doctor; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; School of Medicine; KoƧ University Hospital; N/A; 168021; N/A; 230719; 269567; 239432
    N/A
  • Thumbnail Image
    PublicationOpen Access
    Hiv-associated non hodgkin lymphoma: a case series study from Turkey
    (African Traditional Herbal Medicine Supporters Initiative, 2020) Somay, Kayra; ƇƶpĆ¼r, Sidar; Osmanbaşoğlu, Emre; Masyan, Helin; Arslan, Harun; Akay, Olga Meltem; Tekin, SĆ¼da; Ferhanoğlu, Ahmet Burhan; Researcher; Faculty Member; Faculty Member; School of Medicine; KoƧ University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 18320
    Background: human immunodeficiency virus (HIV) is a global health concern with major risks for opportunistic infections and predisposition to malignancies including Kaposi sarcoma associated with Human Herpes Virus-8 (HHV-8) and non-Hodgkin lymphoma (NHL) commonly associated with Epstein Barr Virus (EBV). Although the exact mechanisms of predisposition to certain malignancies are unclear, HIV (+) cancer patients typically have poorer prognosis. Materials and methods: we included all five HIV positive NHL patients receiving antiretroviral therapy (ART) and chemotherapy in our clinic and aim to determine their follow-up outcomes associated with ART. Results: the use of ART in conjunction with chemotherapy regimens lead to better therapeutic outcome in our cases with no mortality over three years of follow-up despite high rates of poor prognostic factors and studies demonstrating 1-year survival rates of approximately 30% in HIV-associated lymphoma. No significant adverse effect has been recorded. Conclusion: we recommend use of ART along with chemotherapy regimens in HIV positive lymphoma patients for better treatment response.
  • Thumbnail Image
    PublicationOpen Access
    Immature platelet fraction: is a novel early predictive marker for disease severity in patients with Covid-19 pneumonia?
    (De Gruyter, 2021) Taşdemir, Zeynep Atam; Paloğlu, Kerim Erhan; Ä°ncir, Said; Komesli, Zeynep; BaygĆ¼l, Arzu Eden; Ƈaltı, Hatice Kant; Kapmaz, Mahir; Tekin, SĆ¼da; KılıƧ, Alparslan; Dağel, Tuncay; Okan, Ayşe; Somay, Kayra; Akpınar, Timur SelƧuk; Faculty Member; Doctor; Doctor; Faculty Member; School of Medicine; KoƧ University Hospital; N/A; N/A; 272290; N/A; N/A; 42146; N/A; N/A; N/A; N/A; N/A
    Objectives: in many diseases, immature platelet fraction (IPF%) is related to coagulopathy and poor outcome. This study aimed to investigate the predictive value of IPF% for the severity of pneumonia in patients with Coronavirus Disease 2019 (COVID-19). Methods: a total of 154 patients with COVID-19 infections were included. The patients were divided into two groups according to the severity of pneumonia (severe and nonsevere) regarding their oxygen demand. Results: given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p<0.001). Mean platelet volume (p<0.001), platelet-large cell ratio (p=0.001), platelet distribution width (p=0.001), D-Dimer (p<0.001), INR (p=0.003), and aPTT (p=0.007) were also found to be significantly higher in the severe group. Moreover, IPF (p=0.014, Odds ratio = 2.000, 95%CI: 1.149-3.482) was an independent predictor for the severity. The curve value from receiver operating characteristics was 0.879 (p<0.001, 95%CI: 0.784-0.943) for determining the severity of pneumonia. IPF% had a sensitivity and specificity value of 69.5 and 92.4% to detect the disease's severity. Conclusions: IPF% is an independent predictor for the severity of COVID-19 pneumonia. Assessment of IPF% may both help to early determine high-risk patients with COVID-19 and to alert the physicians. / AmaƧ: pek Ƨok hastalıkta, immatĆ¼r platelet fraksiyonu (%Ä°PF), koagĆ¼lopati ve kƶtĆ¼ sonuƧla ilişkilidir. Bu Ƨalışma, Coronavirus Hastalığı 2019 (COVID-19) olan hastalarda pnƶmoni şiddeti iƧin %Ä°PFā€™nin prediktif değerini araştırmayı amaƧladı. Yƶntem: COVID-19 enfeksiyonu olan toplam 154 hasta dahil edildi. Hastalar, oksijen ihtiyaƧları gƶz ƶnĆ¼ne alınarak pnƶmoni şiddetine gƶre (ağır ve ağır olmayan) iki gruba ayrıldı. Bulgular: laboratuvar parametrelerine bakıldığında, medyan Ä°PF yĆ¼zdesi ağır grupta anlamlı olarak daha yĆ¼ksekti (% 11.9?a karşı %3.9, p<0.001). Ortalama trombosit hacmi (p<0.001), trombosit-bĆ¼yĆ¼k hĆ¼cre oranı (p=0.001), trombosit dağılım genişliği (p=0.001), D-Dimer (p<0.001),Ä°NR (p=0.003) ve aPTT (p=0.007) ağır grupta anlamlı olarak daha yĆ¼ksek bulundu. Ayrıca, Ä°PF (p=0.014, Odds oranı = 2.000, %95 CI: 1.149-3.482) hastalık şiddeti iƧin bağımsız bir ƶngƶrdĆ¼rĆ¼cĆ¼ olarak bulundu. Algılayıcı işletim eğrisinden gelen eğri değeri, pnƶmoni şiddetini belirlemek iƧin 0.879 (p<0.001, % 95 CI: 0.784-0.943) idi. Ä°PF, hastalığın şiddetini saptamak iƧin %69.5?lik duyarlılık ve %92.4?lĆ¼k ƶzgĆ¼llĆ¼k değerine sahipti. SonuƧ: Ä°PF, COVID-19 pnƶmonisinin şiddeti iƧin bağımsız bir ƶngƶrĆ¼cĆ¼dĆ¼r. %Ä°PFā€™nin değerlendirilmesi, hem COVID-19? lu yĆ¼ksek riskli hastaları erken belirlemeye hem de hekimleri uyarmaya yardımcı olabilir.
  • Thumbnail Image
    PublicationOpen Access
    The role of obesity in predicting the clinical outcomes of COVID-19
    (Karger Publishers, 2021) Şahin, Serdar; Yağız ƖzgĆ¼l, Yeliz; Yıldırım, Murat; İƧli, Tevhide BetĆ¼l; Polat Korkmaz, Ɩzge; Durcan, Emre; Sulu, Cem; BƶrekƧi, Şermin; Yazıcı, Tabak, Fehmi; Dikmen, Yalim; Ɩzkaya, Hande Mefkure; Gƶnen, Mustafa Sait; Damcı, Taner; Ä°lkova, Hasan; Yumuk, Volkan Demirhan; ƇiƧek, Ebru; Dereli, Dilek Yazıcı; Deyneli, Oğuzhan; ErgƶnĆ¼l, Ɩnder; Sezer, Havva; Somay, Kayra; Bekdemir, Bahar; Faculty Member; Faculty Member; Faculty Member; Teaching Faculty; School of Medicine; KoƧ University Hospital; 179659; 171914; 110398; N/A; N/A; N/A
    Introduction: the aim of this was to describe the predictors of mortality related to COVID-19 infection and to evaluate the association between overweight, obesity, and clinical outcomes of COVID-19. Methods: we included the patients >18 years of age, with at least one positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction. Patients were grouped according to body mass index values as normal weight <25 kg/m(2) (Group A), overweight from 25 to <30 kg/m(2) (Group B), Class I obesity 30 to <35 kg/m(2) (Group C), and >= 35 kg/m(2) (Group D). Mortality, clinical outcomes, laboratory parameters, and comorbidities were compared among 4 groups. Results: there was no significant difference among study groups in terms of mortality. Noninvasive mechanical ventilation requirement was higher in group B and D than group A, while it was higher in Group D than Group C (Group B vs. Group A [p = 0.017], Group D vs. Group A [p = 0.001], and Group D vs. Group C [p = 0.016]). Lung involvement was less common in Group A, and presence of hypoxia was more common in Group D (Group B vs. Group A [p = 0.025], Group D vs. Group A [p < 0.001], Group D vs. Group B [p = 0.006], and Group D vs. Group C [p = 0.014]). The hospitalization rate was lower in Group A than in the other groups; in addition, patients in Group D have the highest rate of hospitalization (Group B vs. Group A [p < 0.001], Group C vs. Group A [p < 0.001], Group D vs. Group A [p < 0.001], Group D vs. Group B [p < 0.001], and Group D vs. Group C [p = 0.010]). Conclusion: COVID-19 patients with overweight and obesity presented with more severe clinical findings. Health-care providers should take into account that people living with overweight and obesity are at higher risk for COVID-19 and its complications.